AI in Drug Discovery Market to Reach USD 15,536.2 Million by 2033 at 25.1% CAGR | Coherent Market Insights

The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.

11/12/2026, 3:40 AM • GlobeNewswire

JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?

Novo Nordisk exceeded JPMorgan's expectations with strong Wegovy pill sales, accumulating over 8 million prescriptions. However, the company is in a transition phase toward a high-volume/low-price model, causing operating profit to fall 9% year-over-year. While the stock has fallen 70% from its 2024 peak and offers an attractive 4.4% dividend yield, investors should weigh the company's strategic shift against competition from Eli Lilly and other GLP-1 drug makers.

11/11/2026, 9:15 PM • The Motley Fool

GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight

DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.

11/11/2026, 1:00 PM • GlobeNewswire

Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and care

Novo Nordisk announced a USD 200 million commitment to the World Diabetes Foundation for 2027-2036 to strengthen diabetes prevention and care in low- and middle-income countries. The 10-year funding will support WDF's efforts to enhance equitable access and scale regional responses to the growing global diabetes crisis affecting 589 million adults.

11/11/2026, 4:30 AM • GlobeNewswire

Type 2 Diabetes Clinical Trial and Competitive Landscape Analysis: 200+ Key Companies Shaping the Future of Type 2 Diabetes Therapeutics Space | DelveInsight

DelveInsight released a comprehensive report on the Type 2 Diabetes competitive landscape, analyzing 200+ pipeline drugs from 170+ active players. The report highlights recent approvals including Eli Lilly's FOUNDAYO (orforglipron) and Novo Nordisk's once-weekly insulin options, alongside promising pipeline therapies targeting various mechanisms of action. Key developments include positive Phase III results for CagriSema, elecoglipron, and other novel GLP-1 receptor agonists, with approximately 60+ drugs in late-stage development.

11/10/2026, 1:00 PM • GlobeNewswire

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

11/10/2026, 11:00 AM • GlobeNewswire

Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?

Eli Lilly has surged over 50% in the past year with 39% revenue growth driven by its GLP-1 drugs Zepbound and Mounjaro, but trades at a steep 45x P/E ratio. Novo Nordisk has lagged with only 6% revenue growth but trades at just 10x earnings and could see significant upside if its higher-dose Wegovy gains traction. The author favors Novo Nordisk as the better value play despite Eli Lilly's superior growth, citing valuation concerns and increased competition ahead.

11/10/2026, 10:44 AM • The Motley Fool

Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028

Pfizer plans to enter the GLP-1 market in 2028 with berobenatide, acquired through its Metsera purchase. Despite a late entry compared to competitors, Pfizer believes its strong commercial execution capabilities, operational scale, and expertise in rapid product rollout (demonstrated with COVID vaccine/pill) position it to become a market leader in the projected $190 billion GLP-1 market by 2035.

11/09/2026, 9:45 AM • The Motley Fool

Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.

Eli Lilly's market capitalization has grown to nearly 9 times that of Novo Nordisk, driven by their dominance in the GLP-1 weight loss drug market. Lilly captured 63% U.S. market share by early 2025 compared to Novo's 36%, aided by superior manufacturing infrastructure, greater weight loss efficacy of tirzepatide (20% vs. 14%), and advantages of its oral drug Foundayo. Meanwhile, Novo faced setbacks including mixed data on CagriSema and a failed heart drug trial.

11/09/2026, 6:10 AM • The Motley Fool

Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?

Novo Nordisk's Wegovy GLP-1 weight-loss pill has surpassed 5 million prescriptions and is outperforming the company's injectable version, supporting its strategic shift to a volume-driven business model. However, the company faces headwinds from lower pricing, weak earnings, and intensifying competition from Eli Lilly's rival GLP-1 pill. The stock offers an attractive 4.4% dividend yield and historically cheap valuation, making it appealing for aggressive dividend investors willing to bet on the turnaround, though more conservative investors should wait for clearer progress on profitability.

11/08/2026, 3:15 PM • The Motley Fool

Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway?

Novo Nordisk reported strong Q3 2026 results driven by its oral weight-loss pill, which generated $810 million in revenue with over 3 million prescriptions. The company raised its full-year guidance and the stock jumped 6% post-earnings. With upcoming catalysts including international expansion of oral Wegovy, new product launches like CagriSema, and promising pipeline candidates, analysts suggest the company is staging a comeback after a difficult two-year period.

11/07/2026, 6:20 PM • The Motley Fool

Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

While Eli Lilly dominates the GLP-1 weight-loss drug market and Novo Nordisk struggles to regain ground, Pfizer is positioning itself as a surprise contender. After dropping its original GLP-1 candidate, Pfizer acquired an alternative drug in development and is now running 10 late-stage trials. The company's key differentiator is a monthly injection option, which could offer greater convenience than competitors' weekly or daily dosing. With a high dividend yield of 5.5% and an inflection point potentially closer than Wall Street believes, Pfizer may represent an overlooked opportunity for long-term dividend investors.

11/07/2026, 4:15 PM • The Motley Fool

Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors

Ginkgo Bioworks announced a strategic shift toward commercializing autonomous laboratory hardware and cloud data services. The company secured its first major pharma partnership with Novo Nordisk to build an autonomous lab, improved liquidity with $285 million in cash and no debt, and reduced R&D expenses by 48% year-over-year. The company is positioning itself to capitalize on AI developers' demand for physical laboratory data generation.

11/07/2026, 2:31 PM • The Motley Fool

Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?

Eli Lilly raised its 2026 revenue guidance to $91-92 billion from $85-87 billion, driven by strong GLP-1 drug sales including Mounjaro and Zepbound. Despite a 57% stock run-up and expensive 47x P/E valuation, the author argues the stock remains a buy due to massive untapped market potential for GLP-1 drugs across obesity, cardiovascular disease, addiction treatment, and potentially anti-aging applications.

11/07/2026, 1:30 PM • The Motley Fool

Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?

The article compares two healthcare disruptors: Hims & Hers Health, a high-growth telehealth platform with 59% revenue growth but facing regulatory scrutiny, and Intuitive Surgical, a dominant medical robotics leader with strong profitability and a 12% increase in installed systems. While both stocks declined in 2026, the author recommends Intuitive Surgical for its stronger competitive moat and market position, despite both being considered speculative investments.

11/06/2026, 10:05 PM • The Motley Fool